anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Combining resuscitative endovascular balloon occlusion of the aorta (REBOA) and the inferior vena cava (REBOVC) with open surgery is a new hybrid approach for treating retrohepatic vena caval injuries. We compared endovascular total hepatic isolation with supraceliac REBOA ± suprahepatic REBOVC and no occlusion in experimental retrohepatic vena cava bleeding regarding survival, bleeding volume, hemodynamic stability, and arterial collateral blood flow.
METHODS: Twenty-five anesthetized pigs (n = 6-7/group) were randomized to REBOA; REBOA + REBOVC; REBOA + infra and suprahepatic REBOVC + portal vein occlusion (endovascular Heaney maneuver, four-balloon-occlusion, 4BO) or no occlusion. After balloon inflation, free bleeding was initiated from an open sheath in the retrohepatic vena cava. Bleeding volume, right internal thoracic artery (RITA) blood flow, hemodynamics, and arterial blood variables were measured until death or up to 90 min.
RESULTS: The REBOA group had a longer median survival time (63 min) compared with the 4BO (24 min, P = 0.02) and no occlusion (30 min, P = 0.02) groups, not versus the REBOA + REBOVC group (49 min, P > 0.05). The first 15 min accumulated bleeding was comparable in all groups (P > 0.05); Thereafter, bleeding volume was higher in the REBOA group versus the 4BO group (P < 0.05), not versus the other groups. RITA blood flow and MAP were higher in the REBOA group versus the other groups after 10 min of bleeding (P < 0.05).
CONCLUSIONS: Endovascular Heaney maneuver was not beneficial for survival or hemodynamic stability in this porcine model, whereas supraceliac REBOA was. Anatomical differences in thoracoabdominal collaterals between pigs and humans must be considered when interpreting these results.
The aim of this study was to explore psychiatric nurse's experiences of caring for people with auditory hallucinations in an acute unit. A qualitative study was conducted using thematic analysis. The study involved semi-structured interviews with 18 acute unit nurses all of whom provided interventions to patients with auditory hallucinations. Overall, participants identified their role in the management of risk within an acute unit, the importance of their therapeutic role and a perceived over-reliance on medication administration as a primary nursing intervention. These findings thus demonstrate the personal and professional conflict that nurses face when working in an acute unit with patients who experience auditory hallucinations. Nurses are in a prime position to provide effective interventions and assistance for people with auditory hallucinations in an acute unit. The findings of this study indicate that mental health nurses may require additional support and education to provide care in a truly recovery-based manner, with training in specific interventions and engagement skills for people who hear voices. Due to an unpredictable environment and sometimes high-risk workplace, nurses may also benefit from organisational assistance in this area.
An aqueous personal cleansing composition comprising (i) 2-20% wt of anionic surfactant(s), (ii) 1-10% wt of amine oxide surfactant(s) and (iii) 0.5-3% wt of a hydrophobically modified alkali-swellable acrylic emulsion (HASE) polymer, as polymer solids, wherein the composition is capable of suspending water insoluble or partially water soluble substances in the form of particles or liquid droplets. The HASE polymer may be an acrylate/steareth-20 methacrylate copolymer, an acrylate/beheneth-25 methacrylate copolymer or an acrylate/palmeth-25 acrylate crosspolymer, preferably at an amount of 1-2% by weight. A preferred anionic surfactant is sodium laureth sulphate (SLES) at an amount of 5-15% wt and preferred amine oxide surfactants are lauramine oxide, myristamine oxide, cocamine oxide, lauramidopropyl amine oxide, myristamidopropyl amine oxide and cocamidopropyl amine oxide, at an amount of 1-5% wt. The composition may further comprise electrolytes, such as NaCl, liquefied gases, e.g. hydrocarbons, and several other ingredients. It is in liquid or gel form and it may be used as a body wash, facial wash or hand wash, for washing hair or as a shaving gel. It is able to incorporate particulate exfoliants (e.g. scrub particles), encapsulates (containing e.g. fragrance oils, moisturising oils or pigments) or oil droplets in suspension.
OBJECTIVE: To determine the association between brain MRI abnormalities and incident epilepsy in older adults.
METHODS: Men and women (ages 45-64 years) from the Atherosclerosis Risk in Communities study were followed up from 1987 to 2018 with brain MRI performed between 2011 and 2013. We identified cases of incident late-onset epilepsy (LOE) with onset of seizures occurring after the acquisition of brain MRI. We evaluated the relative pattern of cortical thickness, subcortical volume, and white matter integrity among participants with incident LOE after MRI in comparison with participants without seizures. We examined the association between MRI abnormalities and incident LOE using Cox proportional hazards regression. Models were adjusted for demographics, hypertension, diabetes, smoking, stroke, and dementia status.
RESULTS: Among 1251 participants with brain MRI data, 27 (2.2%) developed LOE after MRI over a median of 6.4 years (25-75 percentile 5.8-6.9) of follow-up. Participants with incident LOE after MRI had higher levels of cortical thinning and white matter microstructural abnormalities before seizure onset compared to those without seizures. In longitudinal analyses, greater number of abnormalities was associated with incident LOE after controlling for demographic factors, risk factors for cardiovascular disease, stroke, and dementia (gray matter: hazard ratio [HR]: 2.3, 95% confidence interval [CI]: 1.0-4.9; white matter diffusivity: HR: 3.0, 95% CI: 1.2-7.3).
INTERPRETATION: This study demonstrates considerable gray and white matter pathology among individuals with LOE, which is present prior to the onset of seizures and provides important insights into the role of neurodegeneration, both of gray and white matter, and the risk of LOE.
The invention relates to small molecular donkey-hide gelatin pure powder tablets and a preparation method thereof. The small molecular donkey-hide gelatin pure powder tablets take small molecular donkey-hide gelatin as a raw material for the first time, and are processed into tablets without any auxiliary material (the tablets being lozenge tablets or swallowing tablets except for specific explanation). The appearance and hardness of the tablets meet quality standards of tablets. The small molecular donkey-hide gelatin pure powder tablets take 10-30 meshes of small molecular donkey-hide gelatin that contains 2-15 wt% of water and 2-9 wt% of total sugar as a sole raw material and obtained by directly tabletting. The tablets prepared by the preparation process have low granulating rate and lobes rate and good appearance, with hardness, disintegration and friability of the tablets meeting the quality requirements of tablets. The small molecular donkey-hide gelatin pure powder tablets are easy to carry, convenient for taking and accurate in dosage, thereby enlarging suitable population of the donkey-hide gelatin.
PURPOSE:To provide a SMANCS preparation dispersible in administration and consisting of a freeze-dried pharmaceutical composition composed of SMANCS and a phospholipid and an oily contrasting agent for dispersing said pharmaceutical composition. CONSTITUTION:A neocartinostatin derivative having styrene-maleic acid copolymer residue (SMANCS) is mixed with fine particles of a phospholipid (e.g. lecithin) and the mixture is freeze-dried. The objective composition can be produced by dispersing an oily contrasting agent (e.g. iodinated poppy oil fatty acid ethyl ester) optionally in the presence of ethanol or a medium-chain fatty acid monoglyceride. The amount of the oily contrasting agent is 0.25-5.0ml per 1mg of SMANCS in the freeze-dried pharmaceutical composition. The activity of SMANCS can be stably maintained in the freeze-dried pharmaceutical composition even after the storage over a long period. The composition can be easily dispersed in the oily contrasting agent in use.
BACKGROUND: As a novel marker of inflammation, the neutrophil-to-lymphocyte ratio (NLR) has been studied in various diseases. However, NLR in idiopathic membranous nephropathy (IMN) has been rarely studied. We sought to assess the role of NLR in predicting proteinuria remission in IMN.
METHODS: This retrospective study involved 561 patients with IMN from January 2018 to December 2022 in Department of Nephrology of Wuhan Central Hospital. All baseline data were collected before the immunosuppressive regiment was administered. The Cox proportional hazards model and Kaplan-Meier curve were applied to assess the prognostic value of NLR for proteinuria remission.
RESULTS: The area under the receiver operating characteristic curve revealed that the optimal cut-off NLR value for predicting proteinuria non-remission was 2.63, with a sensitivity and specificity of 58.2% and 72.7%, respectively. Kaplan-Meier curves showed a lower rate of proteinuria remission in patients with high NLR compared with low NLR (Log-rank = 5.04, p = 0.025). Multivariate Cox regression analysis showed that high NLR was an independent risk factor for proteinuria non-remission after adjustment (HR = 1.579, 95% CI 1.052-2.683, p = 0.023). Subgroup analysis indicated that high NLR was a risk factor for proteinuria non-remission especially in IMN patients with 24 h proteinuria ≥ 1 g (HR = 1.818, 95% CI 1.031-2.573, p = 0.012) and chronic kidney disease (CKD) stage 3-4 (HR = 1.935, 95% CI 1.084-2.495, p = 0.015).
CONCLUSION: The current study shows that NLR is an independent risk factor for proteinuria non-remission in IMN. More attention should be paid to IMN patients with high NLR, especially for those patients with 24 h proteinuria ≥ 1 g and CKD stage 3-4.
Chronic neuropathic pain has been one of the prominent causes of disability, and acupuncture has shown promise in treatment. The present study aimed to characterize acupuncture modulation of chronic neuropathic pain and explore the related functional brain changes. Sixty chronic sciatica patients were divided into acupuncture- or sham acupuncture groups and received 10 sessions of treatment during 4 weeks. The visual analog scale for leg pain, oswestry disability index (ODI), and resting-state functional magnetic resonance images were assessed at baseline and after treatment. Then, fractional amplitudes of low-frequency fluctuations (fALFF) and support vector regression analyses were performed. Compared with sham acupuncture, acupuncture significantly improved symptoms, including visual analog scale for leg pain and ODI. In addition, acupuncture exhibited increased fALFF of the right superior parietal lobule (SPL) and right postcentral gyrus. Furthermore, the actual 4-week ODI values were positively correlated with the support vector regression-predicted values based on the right SPL fALFF and baseline clinical measurements. These results indicate that the spontaneous neural activity of the right SPL and right postcentral gyrus may be involved in the modulation of acupuncture in chronic neuropathic pain. In addition, the spontaneous neural activity of the right SPL might be used as the predictor of response to acupuncture therapy. PERSPECTIVE: This clinical neuroimaging study elucidated the neural basis of acupuncture in chronic sciatica. Neurological indicators and clinical measurements could be used as potential predictors of acupuncture response. This study combines neuroimaging and artificial intelligence techniques to highlight the potential of acupuncture for the treatment of chronic neuropathic pain. TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry, ChiCTR2100044585, http://www.chictr.org.cn.
PROBLEM TO BE SOLVED: To prepare a skin cosmetic, capable of preventing skin from aging in the skin outer layer by exposure to ultraviolet rays and capable of manifesting skin moisture retaining effects and keratin improving effects by using an extract from a specific plant and one or more ultraviolet light protective agents in combination. SOLUTION: This cosmetic is prepared by formulating an extract from a plant belonging to the genus Betula of the family Betulaceae and/or an extract from a plant of the genus Alnus of the same family with one or more ultraviolet light protective agents (preferably 0.001-20wt.%) in combination. For example, Betula platyphylla var. japonica and Betula platyphylla var. szechanica are cited as the plant belonging to the genus Betula of the family Betulaceae and Alnus japonica, Alnus japonica var. arguta, etc., are cited as the plant belonging to the genus Alnus of the same family. The amount of the formulated extract is preferably 0.001-10wt.% based on the total amount of the cosmetic. For example, p-aminobenzoic acid and titanium oxide are cited as the ultraviolet light protective agent.
BACKGROUND: Tumor angiogenesis inhibitors have been applied for non-small cell lung cancer (NSCLC) therapy. However, the drug resistance hinders their further development. Intercellular crosstalk between lung cancer cells and vascular cells was crucial for anti-angiogenenic resistance (AAD). However, the understanding of this crosstalk is still rudimentary. Our previous study showed that Glioma-associated oncogene 1 (Gli1) is a driver of NSCLC metastasis, but its role in lung cancer cell-vascular cell crosstalk remains unclear.
METHODS: Conditioned medium (CM) from Gli1-overexpressing or Gli1-knockdown NSCLC cells was used to educate endothelia cells and pericytes, and the effects of these media on angiogenesis and the maturation of new blood vessels were evaluated via wound healing assays, Transwell migration and invasion assays, tube formation assays and 3D coculture assays. The xenograft model was conducted to establish the effect of Gli1 on tumor angiogenesis and growth. Angiogenic antibody microarray analysis, ELISA, luciferase reporte, chromatin immunoprecipitation (ChIP), bFGF protein stability and ubiquitination assay were performed to explore how Gli1 regulate bFGF expression.
RESULTS: Gli1 overexpression in NSCLC cells enhanced the endothelial cell and pericyte motility required for angiogenesis required for angiogenesis. However, Gli1 knockout in NSCLC cells had opposite effect on this process. bFGF was critical for the enhancement effect on tumor angiogenesis. bFGF treatment reversed the Gli1 knockdown-mediated inhibition of angiogenesis. Mechanistically, Gli1 increased the bFGF protein level by promoting bFGF transcriptional activity and protein stability. Importantly, suppressing Gli1 with GANT-61 obviously inhibited angiogenesis.
CONCLUSION: The Gli1-bFGF axis is crucial for the crosstalk between lung cancer cells and vascular cells. Targeting Gli1 is a potential therapeutic approach for NSCLC angiogenesis.
An update on the antenatal diagnosis of agenesis of ductus venosus (ADV) by differentiating the various possible types of shunts, focusing on the associated fetal anomalies, and predicting neonatal outcomes. This study reviewed the experience of two tertiary referral centers and literature. An unfavorable outcome was detected in preterm fetuses (p = 0.017), fetuses with a genetic anomaly (p = 0.046) or other associated malformations (p < 0.001). 71% of ADVs with other anomalies had an extrahepatic ADV (p = 0.002). 76% of fetuses with Fetal Growth Restriction (FGR) had an extrahepatic ADV (p = 0.025). ADV may negatively influence fetal growth in cases with extrahepatic vein drainage.
Functional endoscopic sinus surgery is an important procedure for controlling a variety of sinus disease. Given the proximity to the brain and vascularity of tissues, good visualization is paramount. Intraoperative bleeding and obscure the view of the surgeon. In this study, the investigators will use a neuromodulation device that will decrease bleeding and lead to better surgical conditions during the surgery. The device used has already been studied in other bleeding environments. The investigators believe it will also work for this case. The study on Functional Endoscopic Sinus Surgery (FESS) will focus on the use of an innovative device designed to control bleeding and enhance visualization during surgery. FESS, a critical procedure for treating sinus-related conditions, often faces challenges related to bleeding and poor visibility, impacting surgical outcomes. This study aims to address these challenges by introducing a device used in other areas that promises to revolutionize the standard procedure. The device for the study, the Spark Biomedical Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN) System, should decrease bleeding, a common obstacle in sinus surgery. This not only improves visibility for the surgeon but is also expected to lead to more accurate surgical interventions, reduced operation times, and fewer complications. The study will explore the efficacy and safety of this device, making a significant contribution to the field of sinus surgery and medical technology. This technology has been used in other areas, namely opiate use disorder, for which it has an FDA approval. The investigators plan to conduct a detailed investigation into the device's performance, employing a methodology that may include randomized controlled trials, adequate sample sizes, and comprehensive data collection methods. The study will assess various parameters such as the effectiveness of bleeding control, the impact on surgical duration, and overall patient outcomes. This research is not only significant for its potential to improve surgical techniques but also for its broader implications in patient care and medical innovation. By testing the hypotheses related to the device's performance and expected outcomes, the study aims to provide valuable insights that could transform the practice of sinus surgery, enhancing patient safety and surgical efficiency.
Simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in a normal volunteer study and in a hypercholesterolemic patient study, respectively. With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly. In such patients, prothrombin time should be determined before starting VYTORIN and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of VYTORIN is changed or discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.

Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males. There have been post-marketing reports of increased INR in patients who had ezetimibe added to warfarin. Most of these patients were also on other medications.

The effect of VYTORIN on the prothrombin time has not been studied.
The invention relates to a traditional Chinese medicine for treating hepatic fibrosis. The traditional Chinese medicine is prepared from 15 parts by weight of pectinate neopallasia herb, 12 parts by weight of root and leaf of Blastus cochinchinensis Lour., 12 parts by weight of Elsholtzia rugulosa Hemsl., 14 parts by weight of root of tubeflower duchmans pipe, 16 parts by weight of root of cornus chinense wanger, 20 parts by weight of Tofieldia divergens Bur. et Fra-nch., 17 parts by weight of molded dried vegetable, 15 parts by weight of Pellioniat soongii(Merr.)Merr., 15 parts by weight of Gaultheria leucocarpa var. cumingiana, 8 parts by weight of fruit of Thladiantha dubia Bunge, 10 parts by weight of Hemiboea henryi Clarke, 15 parts by weight of ardisia maculosa mez, 12 parts by weight of desmodium triquetrum, 12 parts by weight of commelina paludosa, 14 parts by weight of Castanopsis ceratacantha Rehd. et Wils., 15 parts by weight of Hemsleya sphaerocarpa, 12 parts by weight of Viola diamantiaca Nakai, 14 parts by weight of Lophanthus krylovii Lipsky, 14 parts by weight of root of Campanula colorata Wall., 16 parts by weight of fruit of Phyllanthus emblica L. and 14 parts by weight of Chinese tuliptree bark. A clinical test proves that the traditional Chinese medicine can effectively treat hepatic fibrosis.
Circular RNAs (circRNAs) are engaged in various types of cancers. This study aimed to investigate the roles of circ_0006743 (circ_JMJD1C) in breast cancer. The downstream of circ_JMJD1C and their interaction network was determined by bioinformatic analyses. Gene expression were analyzed through western blot and qRT-PCR assays. Functional assays were conducted in vitro and in vivo to verify circ_JMJD1C role in BC. FISH and confocal analysis indicated the cellular distribution of circ_JMJD1C. Luciferase reporter, RNA immune-precipitation (RIP) assays, as well as Pearson's correlation analysis, were implemented to test the relation of miR-182-5p, JMJD1C and circ_JMJD1C. Circ_JMJD1C and JMJD1C expression were both elevated, and their expression was positively correlated in BC. Circ_ JMJD1C knockdown hindered BC cell proliferation, invasion, and migration, along with epithelial-mesenchymal transition (EMT) in vitro and in vivo. Circ_JMJD1C facilitated BC progression by the miR-182-5p-JMJD1C axis. Circ_JMJD1C epigenetically upregulated SOX4. Circ_JMJD1C promotes the aggressiveness of BC via regulating miR-182-5p/JMJD1C/SOX4 axis. This may provide a novel and promising therapy targeting BC.
Amyotrophic Lateral Sclerosis (ALS) is an incurable disease of unknown etiology that in a short time leads to significant impairment of motor functions and death. The frequency of ALS is 4-8/100 000. Mostly it affects people between 40 and 70 years old, but it can occur at a younger age. Since the symptom onset is most frequently in the fifth or sixth decade, ALS is a huge economic burden for the society. There are many studies conducted to treat the disease and prevent it, but currently the medicine offers only one drug that can slow the appearance of disease symptoms but could not stop the progression. Yet, improvements in medical management, including nutrition and breathing, regularly increase patient survival - 50% of affected patients live at least 3 or more years after diagnosis; 20% live 5 years or more; and up to 10% will survive more than 10 years. The stem-cell-based therapies could be therefore a new waited strategy for ALS clinical treatment.

Since the clinical course of ALS may vary substantially between patients, we are planning to qualify them with a primarily established clinical course based on a detailed anamnesis and clinical assessment. The goal of our nonrandomized, open label study is to investigate the safety and efficacy of autologous adipose derived mesenchymal regenerative cells (ADRC) transplantation into the individuals with diagnosed amyotrophic lateral sclerosis. In order to select a group of 30 ALS patients for the ADRC treatment, approximately 50 ALS patients will be examined. All patients enrolled will have a documented at least 3-months clinical and electrophisiological observation of ALS disease course prior to study enrollment. Each patient will recive 3 injections of ADRC every 3 months: an intraspinal injection followed by 2 subsequent intrathecal infusions. Safety, adverse events and efficacy will be confirmed by clinical, elecrophisiological ( EMG, MUNIX), neuroimmaging and spirometry together with functional (ALSFRS-R) and objective motor assesment (MRC and dynamometer).